Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Malignant Glioma-Pipeline Review, H1 2015

Malignant Glioma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Malignant Glioma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Malignant Glioma-Pipeline Review, H1 2015', provides an overview of the Malignant Glioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Malignant Glioma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Malignant Glioma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Malignant Glioma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Malignant Glioma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Malignant Glioma Overview 8

Therapeutics Development 9

Pipeline Products for Malignant Glioma-Overview 9

Pipeline Products for Malignant Glioma-Comparative Analysis 10

Malignant Glioma-Therapeutics under Development by Companies 11

Malignant Glioma-Therapeutics under Investigation by Universities/Institutes 13

Malignant Glioma-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Malignant Glioma-Products under Development by Companies 17

Malignant Glioma-Products under Investigation by Universities/Institutes 18

Malignant Glioma-Companies Involved in Therapeutics Development 19

Advantagene, Inc. 19

Eli Lilly and Company 20

iDD biotech SAS 21

Lipopharma Therapeutics SL 22

Merck & Co., Inc. 23

Nuo Therapeutics, Inc. 24

Orbus Therapeutics, Inc. 25

Sanofi 26

Stemline Therapeutics, Inc. 27

ZIOPHARM Oncology, Inc. 28

Malignant Glioma-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

Ad-RTS-IL-12-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ALD-451-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Dendritic Cell Therapy for Malignant Gliomas-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Dendritic Cell Therapy for Oncology-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Dendritic Cell Therapy for Oncology-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Dendritic Cell Therapy for Oncology-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

eflornithine hydrochloride-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

galunisertib-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

GliAtak-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

IDD-004-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

LD-224-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

marizomib-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Minerval-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

pembrolizumab-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

SL-701-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Small Molecule for Brain Cancer and Malignant Glioma-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Vaccine to Target Survivin for Malignant Glioma-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Vaccine to Target Wilm's Tumor 1 for Oncology-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

voxtalisib-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Malignant Glioma-Recent Pipeline Updates 70

Malignant Glioma-Dormant Projects 84

Malignant Glioma-Discontinued Products 85

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 87

Disclaimer 87

List of Tables

Number of Products under Development for Malignant Glioma, H1 2015 9

Number of Products under Development for Malignant Glioma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Malignant Glioma-Pipeline by Advantagene, Inc., H1 2015 19

Malignant Glioma-Pipeline by Eli Lilly and Company, H1 2015 20

Malignant Glioma-Pipeline by iDD biotech SAS, H1 2015 21

Malignant Glioma-Pipeline by Lipopharma Therapeutics SL, H1 2015 22

Malignant Glioma-Pipeline by Merck & Co., Inc., H1 2015 23

Malignant Glioma-Pipeline by Nuo Therapeutics, Inc., H1 2015 24

Malignant Glioma-Pipeline by Orbus Therapeutics, Inc., H1 2015 25

Malignant Glioma-Pipeline by Sanofi, H1 2015 26

Malignant Glioma-Pipeline by Stemline Therapeutics, Inc., H1 2015 27

Malignant Glioma-Pipeline by ZIOPHARM Oncology, Inc., H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Malignant Glioma Therapeutics-Recent Pipeline Updates, H1 2015 70

Malignant Glioma-Dormant Projects, H1 2015 84

Malignant Glioma-Discontinued Products, H1 2015 85

List of Figures

Number of Products under Development for Malignant Glioma, H1 2015 9

Number of Products under Development for Malignant Glioma-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 30

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 34

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advantagene, Inc.

Eli Lilly and Company

iDD biotech SAS

Lipopharma Therapeutics SL

Merck & Co., Inc.

Nuo Therapeutics, Inc.

Orbus Therapeutics, Inc.

Sanofi

Stemline Therapeutics, Inc.

ZIOPHARM Oncology, Inc.

Malignant Glioma Therapeutic Products under Development, Key Players in Malignant Glioma Therapeutics, Malignant Glioma Pipeline Overview, Malignant Glioma Pipeline, Malignant Glioma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com